UBS has downgraded Diasorin's rating from "Buy" to "Neutral," maintaining a price target of 116 euros per share. Analysts note that the company's shares are now valued above the industry's historical premium, reflecting expectations of single-digit revenue growth and double-digit earnings growth. Despite this, they acknowledge significant progress in financial and operational aspects, particularly in the Immunodiagnostics and Molecular Diagnostics divisions.